M Ventures is a venture capital firm that focuses on making direct investments in early-stage companies, particularly in the biotechnology and technology sectors. Headquartered in Amsterdam, the firm targets innovative companies that address significant challenges in healthcare, life sciences, electronics, and sustainability. With a commitment to supporting visionary entrepreneurs, M Ventures seeks to advance transformative ideas that enhance drug development, empower scientific research, and improve technological solutions for information management. The firm plays an active role in its portfolio companies, aiming to foster innovation that can lead to substantial impacts in their respective fields.
Vice President and Head of Performance Materials Fund
Sarah Luppino
Associate
Pia Michel
Analyst
Michael Palank
General Partner
Christian Patze
Associate, Performance Materials
Jennifer Randle
COO
Javier Rodriguez
CFO
Sebastian Schoefer
Senior Associate
Christian Uhrich
Investment Director, Biotechnology team
Christian Uhrich
Investment Director
Bram Vanparys
Director
Ilja Aizenberg
Principal, Technology
Cheryl Zimberlin
Associate
Henry Zubaida
Analyst
Tobias Egle@m
Associate
Daniel Franke
Associate
Past deals in Geneve
Calypso Biotech
Series A in 2021
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
Calypso Biotech
Series A in 2019
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
Prexton Therapeutics
Series B in 2017
Prexton Therapeutics is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It focuses on developing innovative drugs for Parkinson's disease and other brain disorders, utilizing a unique scientific approach that integrates molecular, behavioral, and chemistry technologies. The company targets metabotropic glutamate receptors, specifically mGluR4 and mGluR3, to create novel therapeutic compounds. Prexton Therapeutics aims to enhance the quality of life for patients by providing alternatives to traditional dopaminergic treatments, enabling quicker initiation of therapy and improved medical outcomes. As of March 2018, Prexton operates as a subsidiary of H. Lundbeck A/S.
Prexton Therapeutics
Series A in 2015
Prexton Therapeutics is a biopharmaceutical company based in Geneva, Switzerland, founded in 2012. It focuses on developing innovative drugs for Parkinson's disease and other brain disorders, utilizing a unique scientific approach that integrates molecular, behavioral, and chemistry technologies. The company targets metabotropic glutamate receptors, specifically mGluR4 and mGluR3, to create novel therapeutic compounds. Prexton Therapeutics aims to enhance the quality of life for patients by providing alternatives to traditional dopaminergic treatments, enabling quicker initiation of therapy and improved medical outcomes. As of March 2018, Prexton operates as a subsidiary of H. Lundbeck A/S.
Calypso Biotech
Seed Round in 2013
Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. They operate as a nimble, semi-virtual organization in order to create substantial added value for their investors from a portfolio of unique proprietary antibody candidates.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.